David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.

MAbs

Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah Saudi Arabia.

Published: April 2022

AI Article Synopsis

  • Anti-SARS-CoV-2 monoclonal antibodies and vaccines have been effective in reducing viral loads and hospitalizations, but new variants are evolving that can escape these neutralizing antibodies.
  • Researchers are exploring the use of recombinant angiotensin-converting enzyme 2 (rACE2) as a strategy to block SARS-CoV-2 infection and tackle these variants.
  • Strategies like Fc fusions and site mutations on ACE2 are being utilized to improve its antiviral effectiveness and ensure it solely acts against the virus without affecting its normal function.

Article Abstract

Anti-SARS-CoV-2 monoclonal antibodies and vaccines have shown improvement in lowering viral burden and hospitalization. However, emerging SARS-CoV-2 variants contain neutralizing antibody-escape mutations. Therefore, several reports have suggested the administration of recombinant angiotensin-converting enzyme 2 (rACE2) as a soluble receptor trap to block SARS-CoV-2 infection and limit viral escape potential. Several strategies have been implemented to enhance the efficacy of rACE2 as a therapeutic agent. Fc fusions have been used to improve pharmacokinetics and boost the affinity and avidity of ACE2 decoys for the virus spike protein. Furthermore, the intrinsic catalytic activity of ACE2 can be eliminated by introducing point mutations on the catalytic site of ACE2 to obtain an exclusive antiviral activity. This review summarizes different evolution platforms that have been used to enhance ACE2-Fc (i.e., immunoadhesins) as potential therapeutics for the current pandemic or future outbreaks of SARS-associated betacoronaviruses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986284PMC
http://dx.doi.org/10.1080/19420862.2022.2057832DOI Listing

Publication Analysis

Top Keywords

david versus
4
versus goliath
4
goliath ace2-fc
4
ace2-fc receptor
4
receptor traps
4
traps potential
4
potential sars-cov-2
4
sars-cov-2 inhibitors
4
inhibitors anti-sars-cov-2
4
anti-sars-cov-2 monoclonal
4

Similar Publications

Referral Networks, Racial Inequity, and Hospital Quality for Open Heart Surgery.

Circ Cardiovasc Qual Outcomes

December 2024

RAND Corporation, Santa Monica, CA (C.B.G., C.L.D., S.Z., M.S., L.J.M., I.P.).

Background: Differences in the quality of hospitals where Black and White patients receive coronary artery bypass grafting (CABG) surgery have been documented. We examined the contributions of physician networks to the gap.

Methods: This was a cross-sectional study of all Medicare fee-for-service Black and White patients undergoing elective CABG during 2017 to 2019; the primary care physicians and cardiologists treating them for 12 months before surgery (the patients' physician network); and CABG-performing hospitals within 100 miles of each patient.

View Article and Find Full Text PDF

Background: The COVID-19 pandemic dramatically impacted endoscopy practice. Recommendations were to postpone elective cases, including procedures for removal of luminal neoplasia. This provided a natural experiment to evaluate outcomes related to these decisions and the impact of time to procedure on change in histology.

View Article and Find Full Text PDF

When social comparison works as a demotivator: Stronger peers mitigate effort levels.

Int J Psychophysiol

December 2024

Department of Psychology and Educational Sciences, University of Geneva, Switzerland.

The present study tested the effect of social comparison on effort-related cardiovascular responses. Specifically, we investigated how effort levels are influenced when individuals compare themselves to significantly better peers versus similar or slightly better peers. 43 participants played five-minute video games while displaying the scores of peers who were similar, slightly better, or significantly better, in addition to a control condition without peer scores.

View Article and Find Full Text PDF

Introduction: Psychotropic medication (PM) use in behavioral-variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD.

Methods: We analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study.

View Article and Find Full Text PDF

Objective: This studied investigated whether changes in circulating biomarkers predict progressive pulmonary fibrosis (PFF) in patients with systemic sclerosis-associated interstitial lung disease (ILD) receiving treatment.

Method: Participants of Scleroderma Lung Study (SLS) II, which compared mycophenolate (MMF) versus cyclophosphamide (CYC) for SSc-ILD, who had blood samples at baseline and 12-months were included. Levels for C-reactive protein (CRP), interleukin (IL)-6, chemokine ligand 4 (CXCL4), chemokine ligand 18 (CCL18) and Krebs von den Lungen 6 (KL-6) were measured, and a logistic regression model evaluated relationships between changes in these biomarkers and the development of PPF by 24 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!